Recursion Pharmaceuticals Inc
Closed
SectorHealthcare
3.54 -6.84
Overview
Share price change
24h
Min
3.4699999999999998
Max
3.86
Income | 12M -119M |
|---|---|
Sales | 11M 19M |
EPS | -0.22 |
Profit margin | -641.634 |
Employees | 600 |
EBITDA | -11M -123M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +88.45% upside |
Market Cap | 252M 2.3B |
|---|---|
Previous open | 10.38 |
Previous close | 3.54 |
Recursion Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Recursion Pharmaceuticals Inc Forecast
Price Target
By TipRanks
88.45% upside
12 Months Forecast
Average 6.633 USD 88.45%
High 8 USD
Low 5.9 USD
Based on 4 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.